Key result
Diabetic patients exhibited increased cardiac fibrosis and pathological endothelial-to-mesenchymal transition in the heart, associated with altered expressions of key non-coding RNAs.
Why the study?
EndMT in DCM and associated epigenetic changes needed characterization in human patients, and whether ncRNAs are affected by DNA methylation changes was unknown.
Observational (n=38)
Masked
No
Answers are grounded in this paper and cite their sources.
Suggests ncRNA targets for diabetic cardiomyopathy; leaves open therapeutic efficacy pending validation.
AIMS: Diabetic cardiomyopathy (DCM) is a major complication of diabetes and a risk factor for cardiovascular disease. Endothelial dysfunction is central to DCM, and endothelial-to-mesenchymal transition (EndMT) is a key form of endothelial dysfunction in diabetes. EndMT in DCM has been well-studied in model systems and has been found to be epigenetically regulated by non-coding RNAs (ncRNAs). However, EndMT in DCM and its associated epigenetic changes need further characterization in human patients. It is also not known if ncRNAs are affected by changes in DNA methylation in DCM. This study aims to confirm in human hearts, the findings from animal and cell studies, and potentially provide novel insight into interactions between DNA methylation and ncRNAs in EndMT in DCM. METHODS AND RESULTS: Heart tissues were collected from autopsy patients, fixed in formalin, and embedded in paraffin. Thin sections from paraffin-embedded tissues were used for histology and immunofluorescence analyses, where we confirmed that diabetic patients showed increased cardiac fibrosis that EndMT had occurred. Tissue curls from the paraffin-embedded tissues were used for RT-qPCR and methylation analyses. RT-qPCR quantitatively showed that EndMT occurs in the hearts of diabetics, and that EndMT in human hearts corresponded to changes in key ncRNAs. Methylation analysis showed that some of the EndMT-related ncRNAs were regulated by DNA promoter methylation, while others may be regulated through different epigenetic mechanisms. CONCLUSIONS: We show that EndMT is a relevant pathological process in human hearts during DCM, and that its occurrence coincides with changes in relevant ncRNAs. We further find that interplay between DNA methylation and certain ncRNAs involved in the regulation of EndMT may contribute to the observed changes in ncRNA expression. These findings reinforce the role of EndMT in patients afflicted with DCM and underscore the complexities and importance of the interactions between different facets of epigenetic regulation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an observational in Diabetic cardiomyopathy (n=38). Diabetes vs. Non-diabetic was evaluated on Endothelial-to-mesenchymal transition (EndMT) markers and ncRNA expression. Diabetic patients exhibited increased cardiac fibrosis and pathological endothelial-to-mesenchymal transition in the heart, associated with altered expressions of key non-coding RNAs.
Synapse has enriched 10 related papers. Consider them for comparative context: